Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Necrosis Factor-like Cytokine 1A (TL1A), also known as TNFSF15, is a type II transmembrane protein belonging to the TNF superfamily. It exists as both membrane-bound and soluble forms and plays a critical role in immune regulation, influencing the proliferation, activation, differentiation, and apoptosis of immune cells. TL1A signals primarily through its receptor DR3/TNFRSF25, activating MAPK, NF-kB, and caspase-dependent pathways. It is implicated in various autoimmune and inflammatory diseases, including IBD, rheumatoid arthritis, and asthma, making it a therapeutic target. Anti-TL1A antibodies are under clinical investigation as potential treatments for these conditions.
Monoclonal antibody therapies blocking TL1A pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Necrosis Factor-like Cytokine 1A (TL1A).